Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Acquired Whim Syndrome: A Possible New Side Effect Of Dasatinib!

Satya Prakash Yadav, MBBS, Mohammed Ramzan, Yogi Raj Chopra, Nivedita Dhingra, Anupam Sachdeva, MD

Blood (2013) 122 (21): 4933.

https://doi.org/10.1182/blood.V122.21.4933.4933

Published: 2013

Journal Articles

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Anthony H. Goldstone, Susan M. Richards, Hillard M. Lazarus, Martin S. Tallman, Georgina Buck, Adele K. Fielding, Alan K. Burnett, Raj Chopra, Peter H. Wiernik, Letizia Foroni, Elisabeth Paietta, Mark R. Litzow, David I. Marks, Jill Durrant, Andrew McMillan, Ian M. Franklin, Selina Luger, Niculae Ciobanu, Jacob M. Rowe

Blood (2008) 111 (4): 1827–1833.

https://doi.org/10.1182/blood-2007-10-116582

Published: 2008

Includes: Supplemental data

Journal Articles

In Adults with Standard-Risk Acute Lymphoblastic Leukemia (ALL) the Greatest Benefit Is Achieved from an Allogeneic Transplant in First Complete Remission (CR) and an Autologous Transplant Is Less Effective Than Conventional Consolidation/Maintenance Chemotherapy: Final Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

Jacob M. Rowe, MD, Georgina Buck, PhD, Adele Fielding, MD, Martin S. Tallman, MD, Alan K. Burnett, MD, Raj Chopra, MD, Peter H. Wiernik, MD, Susan M. Richards, PhD, Hillard M. Lazarus, MD, Letizia Foroni, MD, Elisabeth Paietta, PhD, Mark R. Litzow, MD, David Marks, MD, Jill Durrant, MD, Anthony H. Goldstone, MD

Blood (2006) 108 (11): 2.

https://doi.org/10.1182/blood.V108.11.2.2

Published: 2006

Journal Articles

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

Steven Knapper, Alan K. Burnett, Tim Littlewood, W. Jonathan Kell, Sam Agrawal, Raj Chopra, Richard Clark, Mark J. Levis, Donald Small

Blood (2006) 108 (10): 3262–3270.

https://doi.org/10.1182/blood-2006-04-015560

Published: 2006

Journal Articles

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993

Hillard M. Lazarus, Susan M. Richards, Raj Chopra, Mark R. Litzow, Alan K. Burnett, Peter H. Wiernik, Ian M. Franklin, Martin S. Tallman, Lucy Cook, Georgina Buck, I. Jill Durrant, Jacob M. Rowe, Anthony H. Goldstone, for the Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group

Blood (2006) 108 (2): 465–472.

https://doi.org/10.1182/blood-2005-11-4666

Published: 2006

Journal Articles

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993

Jacob M. Rowe, Georgina Buck, Alan K. Burnett, Raj Chopra, Peter H. Wiernik, Susan M. Richards, Hillard M. Lazarus, Ian M. Franklin, Mark R. Litzow, Niculae Ciobanu, H. Grant Prentice, Jill Durrant, Martin S. Tallman, Anthony H. Goldstone, for ECOG and the MRC/NCRI Adult Leukemia Working Party

Blood (2005) 106 (12): 3760–3767.

https://doi.org/10.1182/blood-2005-04-1623

Published: 2005

Journal Articles

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Kirsty J. Thomson, MD, Karl S. Peggs, MD, Paul Smith, MSc, Raj Chopra, MD, Jim Cavet, MD, Ann Hunter, MD, Anne Parker, MD, Ruth Pettengell, MD, Don Milligan, MD, Emma C. Morris, MD, Anthony H. Goldstone, MD, David C. Linch, MD, Stephen Mackinnon, MD

Blood (2005) 106 (11): 657.

https://doi.org/10.1182/blood.V106.11.657.657

Published: 2005

Journal Articles

Adult Patients with Acute Lymphoblastic Leukemia (ALL) and Central Nervous System (CNS) Leukemia at Diagnosis May Attain Durable Complete Remissions (CR). Results from the International ALL Trial (MRC UKALL-XII/ECOG E2993).

Hillard M. Lazarus, MD, Sue M. Richards, Raj Chopra, MD, Mark R. Litzow, MD, Alan K. Burnett, MD, Peter H. Wiernik, MD, Ian M. Franklin, MD, Martin S. Tallman, MD, G. Buck, Jill Durrant, Jacob M. Rowe, MD, Anthony H. Goldstone, MD

Blood (2004) 104 (11): 4484.

https://doi.org/10.1182/blood.V104.11.4484.4484

Published: 2004

Journal Articles

No Signs of New Toxicity When Amphotericin B Lipid Complex (ABLC, ABELCET) and Caspofungin Are Used in Combination in the Treatment of FUO.

Rodrigo Martino, Bertrand DuPont, Helen Huckle, Raj Chopra

Blood (2004) 104 (11): 5077.

https://doi.org/10.1182/blood.V104.11.5077.5077

Published: 2004

Journal Articles

Sequential Quantitative Minimal Residual Disease in BCR-ABL Positive Acute Lymphoblastic Leukaemia: Differential Observations between Major and Minor Fusion Gene Rearrangements and Variation Due to Source Material.

Gareth Gerrard, MSc, Wayne Mitchell, PhD, Anthony Goldstone, MD, Raj Chopra, MD, PhD, Georgina Buck, PhD, Sue Richards, DPhil, Letizia Foroni, MD, PhD

Blood (2004) 104 (11): 1093.

https://doi.org/10.1182/blood.V104.11.1093.1093

Published: 2004

Journal Articles

A Phase II Trial of the FLT3 Inhibitor CEP701 as First Line Treatment for Older Patients with Acute Myeloid Leukaemia Not Considered Fit for Intensive Chemotherapy.

Steven Knapper, Alan K. Burnett, Jonathan Kell, Raj Chopra, Richard Clark, Jenny Craig, Dominic Culligan, Mark J. Levis, Nigel H. Russell, Donald Small

Blood (2004) 104 (11): 864.

https://doi.org/10.1182/blood.V104.11.864.864

Published: 2004

Journal Articles

The Outcome of 551 1 st CR Transplants in Adult ALL from the UKALL XII/ECOG 2993 Study.

Anthony H. Goldstone, Hillard J. Lazarus, Sue M. Richards, Mark R. Litzow, Raj Chopra, Alan Burnett, Peter H. Wiernik, Ian M. Franklin, H. G. Prentice, Martin Tallman, G. Harrison, Jill Durrant, Jacob Rowe

Blood (2004) 104 (11): 615.

https://doi.org/10.1182/blood.V104.11.615.615

Published: 2004

Journal Articles

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

William J. Kell, Alan K. Burnett, Raj Chopra, John A. L. Yin, Richard E. Clark, Ama Rohatiner, Dominic Culligan, Ann Hunter, Archie G. Prentice, Donald W. Milligan

Blood (2003) 102 (13): 4277–4283.

https://doi.org/10.1182/blood-2003-05-1620

Published: 2003

Journal Articles

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

Blood (2002) 100 (9): 3121–3127.

https://doi.org/10.1182/blood-2002-03-0701

Published: 2002

Journal Articles

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

Suparno Chakrabarti, Stephen Mackinnon, Raj Chopra, Panagiotis D. Kottaridis, Karl Peggs, Peter O'Gorman, Ronjon Chakraverty, Timothy Marshall, Husam Osman, Premini Mahendra, Charles Craddock, Herman Waldmann, Geoff Hale, Christopher D. Fegan, Kwee Yong, Anthony H. Goldstone, David C. Linch, Donald W. Milligan

Blood (2002) 99 (12): 4357–4363.

https://doi.org/10.1182/blood.V99.12.4357

Published: 2002

Journal Articles

Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation

Richard E. Champlin, Norbert Schmitz, Mary M. Horowitz, Bernard Chapuis, Raj Chopra, Jan J. Cornelissen, Robert Peter Gale, John M. Goldman, Fausto R. Loberiza, Jr, Bernd Hertenstein, John P. Klein, Emilio Montserrat, Mei-Jie Zhang, Olle Ringdén, Sandra C. Tomany, Philip A. Rowlings, Marlies E. H. M. Van Hoef, Alois Gratwohl

Blood (2000) 95 (12): 3702–3709.

https://doi.org/10.1182/blood.V95.12.3702

Published: 2000

NARROW

Acquired Whim Syndrome: A Possible New Side Effect Of Dasatinib!

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993

Improved Outcome Following Reduced Intensity Allogeneic Transplantation in Hodgkin’s Lymphoma Relapsing Post-Autologous Transplantation.

Adult Patients with Acute Lymphoblastic Leukemia (ALL) and Central Nervous System (CNS) Leukemia at Diagnosis May Attain Durable Complete Remissions (CR). Results from the International ALL Trial (MRC UKALL-XII/ECOG E2993).

No Signs of New Toxicity When Amphotericin B Lipid Complex (ABLC, ABELCET) and Caspofungin Are Used in Combination in the Treatment of FUO.

Sequential Quantitative Minimal Residual Disease in BCR-ABL Positive Acute Lymphoblastic Leukaemia: Differential Observations between Major and Minor Fusion Gene Rearrangements and Variation Due to Source Material.

A Phase II Trial of the FLT3 Inhibitor CEP701 as First Line Treatment for Older Patients with Acute Myeloid Leukaemia Not Considered Fit for Intensive Chemotherapy.

The Outcome of 551 1 st CR Transplants in Adult ALL from the UKALL XII/ECOG 2993 Study.

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only